Junji Suzumiya
YOU?
Author Swipe
View article: 65 | UTILITY OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EXTRANODAL NK/T‐CELL LYMPHOMA
65 | UTILITY OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EXTRANODAL NK/T‐CELL LYMPHOMA Open
View article: Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study Open
Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor that is approved for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in Japan based on randomized clinical trial data. The aim of the rea…
View article: Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients
Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients Open
Aim Peripheral T‐cell lymphoma not otherwise specified (PTCL‐NOS) is a heterogeneous disease that can be classified into the PTCL‐TBX21 and PTCL‐GATA3 subtypes. Methods In this study, we compared the clinicopathological features of PTCL‐NO…
View article: Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas Open
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revolutionized the treatment of advanced solid cancers. However, these clinical benefits have been limited to cases of malignant lymphomas, show…
View article: Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma Open
Objective This dose-escalation part of an ongoing Phase I study assessed the tolerability, safety and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Methods Mosunetuzumab …
View article: Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma Open
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) are curative treatment modalities for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available reg…
View article: Supplementary Figure Legend from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Supplementary Figure Legend from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Open
PDF file - 64K
View article: Supplementary Figure 1 from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Supplementary Figure 1 from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Open
PDF file - 86K, 4.Correlation of EBER positivity and EBV-DNA levels in whole blood or plasma
View article: Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients Open
Purpose: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients desp…
View article: Supplementary Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
Supplementary Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients Open
Supplementary Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
View article: Supplementary Figure 1 from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Supplementary Figure 1 from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Open
PDF file - 86K, 4.Correlation of EBER positivity and EBV-DNA levels in whole blood or plasma
View article: Data from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Data from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Open
Purpose: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is an Epstein–Barr virus (EBV)–associated lymphoma for which a new chemotherapeutic regimen called SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) re…
View article: Data from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Data from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Open
Purpose: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is an Epstein–Barr virus (EBV)–associated lymphoma for which a new chemotherapeutic regimen called SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) re…
View article: Supplementary Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
Supplementary Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients Open
Supplementary Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
View article: Supplementary Figure Legend from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Supplementary Figure Legend from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Open
PDF file - 64K
View article: Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients Open
Purpose: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients desp…
View article: A CASE OF DIFFUSE LARGE B-CELL LYMPHOMA TRANSFORMED FROM FOLLICULAR LYMPHOMA WITH SUCCESSFUL GRAFT-VERSUS-LYMPHOMA EFFECT ON EARLY RELAPSE AFTER CORD BLOOD TRANSPLANTATION
A CASE OF DIFFUSE LARGE B-CELL LYMPHOMA TRANSFORMED FROM FOLLICULAR LYMPHOMA WITH SUCCESSFUL GRAFT-VERSUS-LYMPHOMA EFFECT ON EARLY RELAPSE AFTER CORD BLOOD TRANSPLANTATION Open
症例は71歳男性．後腹膜リンパ節腫脹による水腎症にて発症．濾胞性リンパ腫（FL）と診断．経過中びまん性大細胞型B細胞リンパ腫（DLBCL）に形質転換し，化学療法中前胸部に巨大腫瘤残存し化学療法不応となったため，同種造血幹細胞移植（allo-HSCT）目的に当院へ紹介．前胸部腫瘤に対し放射線治療にて寛解後に，フルダラビン，アルケラン，全身放射線照射（TBI）の強度減弱前処置にタクロリムス，ミコフェノール酸モフェチルによる移植片対宿主病（GVHD）予防による臍帯血移植（CBT）…
View article: Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study Open
View article: Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study Open
This multicenter, open‐label, phase I study assessed the safety and antitumor activity of acalabrutinib in Japanese patients with relapsed/refractory (r/r) B‐cell malignancies. Parts 1 (dose confirmation) and 2 (dose expansion) of this thr…
View article: Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report
Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report Open
View article: Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)
Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR) Open
Mantle cell lymphoma (MCL) accounts for approximately 3% of all cases of malignant lymphoma in Japan. The CLIMBER-DBR (Treatment practices and patient burden in chronic lymphocytic leukemia and mantle cell lymphoma patients in the real wor…
View article: Topical Administration of G-CSF Ameliorates Refractory Cutaneous Ulcers: A Clinical Case Series
Topical Administration of G-CSF Ameliorates Refractory Cutaneous Ulcers: A Clinical Case Series Open
Objective: Granulocyte colony-stimulation factor (G-CSF) is a chemokine that stimulates granulocyte proliferation and maturation and mobilizes bone marrow-derived stem cells into the bloodstream. G-CSF treatment has been shown to enhance t…
View article: Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR)
Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR) Open
There are limited real-world data on the treatment practices and healthcare resource utilization associated with chronic lymphocytic leukemia (CLL) in Japan. In this study (CLIMBER-DBR), we performed retrospective analyses of the Japanese …
View article: A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia Open
Objective Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is no…
View article: Advance in the Treatment with Molecular Targeted Drugs for Malignant Lymphoma and Chronic Lymphocytic Leukemia
Advance in the Treatment with Molecular Targeted Drugs for Malignant Lymphoma and Chronic Lymphocytic Leukemia Open
悪性リンパ腫や慢性リンパ性白血病に対する分子病態の解明により，さまざまな分子標的薬が開発されている．B細胞受容体シグナル伝達経路が明らかにされ，それぞれの分子を標的とした有効な薬剤が開発・使用されている．Bruton型チロシンキナーゼ阻害薬イブルチニブは，リツキシマブ併用化学療法に抵抗性の染色体17p欠失/TP53異常を有する慢性リンパ性白血病に対しても有効で，未承認薬のPI3キナーゼ（phosphoinositide 3-kinase：PI3K）阻害薬も海外で使用されてい…
View article: Retraction Note to: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
Retraction Note to: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey Open
View article: Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma Open
View article: Author response for "Hematopoietic stem cell transplantation for diffuse large B‐cell lymphoma having 8q24/ <i>MYC</i> rearrangement in Japan"
Author response for "Hematopoietic stem cell transplantation for diffuse large B‐cell lymphoma having 8q24/ <i>MYC</i> rearrangement in Japan" Open
View article: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma Open
View article: Simultaneous Discordant B-Lymphoblastic Lymphoma and Follicular Lymphoma
Simultaneous Discordant B-Lymphoblastic Lymphoma and Follicular Lymphoma Open
Objectives We report a rare case of B-lymphoblastic lymphoma (B-LBL) and low-grade follicular lymphoma (FL) identified concurrently in biopsies from different sites at the initial diagnosis in a 39-year-old man. The clonal relationship bet…